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OBJECTIVE This study was conducted to assess the impact of GPIIb/IIIa blockade with tirofiban on costs
during the initial hospitalization and at 30 days among patients undergoing high-risk
coronary angioplasty.
BACKGROUND GPIIb/IIIa blockers are a new class of compounds that have been shown in clinical studies to
prevent complications after high-risk angioplasty.
METHODS The RESTORE trial was a multinational, blinded placebo-controlled study of 2,197 patients
randomized to tirofiban or placebo following coronary angioplasty. This economic assessment
was a prospective substudy of the RESTORE trial, and included 1,920 patients enrolled in
the U.S. Costs were estimated for the U.S. cohort based on their utilization of healthcare
resources and on costs measured directly in 820 U.S. patients at 30 sites.
RESULTS There was a 36% difference in the rate of the composite event of death, myocardial infarction
(MI) and revascularization at two days between tirofiban and placebo (8% vs. 12%, p 5
0.002). This difference was attributed to a reduction in nonfatal MI, repeat angioplasty,
coronary surgery and stent placement. These clinical benefits followed a similar trend at 30
days, with a 16% reduction in the composite event (p 5 0.10). In-hospital cost, including
professional and study drug costs, was $12,145 6 5,882 with placebo versus $12,230 6 5,527
with tirofiban (p 5 0.75). The 30-day cost was $12,402 6 6,147 with placebo versus
$12,446 6 5,814 with tirofiban (p 5 0.87).
CONCLUSIONS Tirofiban has been shown to decrease in-hospital and possibly 30-day events after high-risk
angioplasty. The beneficial clinical effects of tirofiban in high-risk patients can be achieved at
no increased cost. (J Am Coll Cardiol 1999;34:1061–6) © 1999 by the American College of
Cardiology
The outcome of coronary angioplasty has gradually im-
proved over the last several years. Nonetheless, acute closure
remains a significant risk, occurring in some 4% to 13% of
patients (1,2). Acute closure is associated with an increased
risk of myocardial infarction (MI), emergent coronary
surgery and death, resulting in increased resource utilization
due to these complications (3). Efforts to decrease acute
closure have been aimed partly at mechanical intervention
(4), as well as at pharmacologic interventions to prevent
thrombosis (5–7). Efforts over the last several years to
understand the pathophysiology of the GPIIb/IIIa receptor
have revealed the importance of this receptor on the platelet
for fibrinogen cross-linking and platelet aggregation (8).
Several specific blockers of this receptor have been devel-
oped and have been evaluated in clinical studies (9).
In the multicenter Randomized Efficacy Study of Tiro-
fiban for Outcomes and Restenosis (RESTORE) trial,
patients were randomized to the specific GPIIb/IIIa recep-
tor blocker tirofiban versus placebo after coronary interven-
tion (7). The RESTORE trial was designed to determine
whether tirofiban could prevent untoward complications
after coronary intervention at 2, 7 and 30 days postproce-
dure. As part of the RESTORE trial, a prospective eco-
nomic analysis of cost was conducted at a subset of sites in
the U.S. An examination of the in-hospital and 30-day
hospital costs associated with the RESTORE trial is the
primary focus of this article.
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METHODS
Patient population. Between January 1995 and November
1995, 2,197 patients with acute MI (n 5 669 nonprimary
percutaneous transluminal coronary angioplasty [PTCA]
for MI and n 5 147 primary PTCA for acute MI) or
unstable angina (n 5 1,381) undergoing angioplasty were
randomized at 111 institutions to tirofiban or placebo. As
described in the main report (7), patients ,80 years old
referred to coronary intervention were eligible if they pre-
sented within 72 h of onset of acute MI or with unstable
angina. Patients were excluded if they had received throm-
bolysis within 24 h of the angioplasty, had severe multivessel
or left main disease, a contraindication to anticoagulation,
severe heart failure or other severe noncardiac problems.
Clinical overview. The design and methods for the
RESTORE trial have been described previously (7). Briefly,
patients received a bolus of 10 mg/kg of tirofiban or placebo
over 3 min, after a guide wire was placed across the lesion.
Patients then received an infusion of 0.10 mg/kg/min for
36 h. Transcatheter revascularization was performed as
clinically indicated. Patients were followed for six months.
The primary end point was the composite of death from all
causes (acute MI, repeat angioplasty, coronary surgery, stent
placement for acute closure or intraaortic balloon counter-
pulsation to relieve refractory angina) and was evaluated at
30 days. The same end point was also evaluated at two and
seven days, as well as at six months. The data were
reevaluated in a post hoc analysis, with repeat angioplasty
replaced by emergent repeat angioplasty to match similar
studies performed with other agents in this class (5,6).
Economic substudy. The economic analysis evaluated in
this trial included medical costs and resource utilization. In
principle, the economic perspective of the study is societal.
However, as costs are not accounted for by society, cost
models were based on payer data. Hospital charges, col-
lected from UB92 forms, were gathered on 820 patients at
30 U.S. centers. Because of variation in healthcare delivery
systems and economics in different countries, the analysis
was limited to the U.S.
Hospital costs were estimated for each patient by multi-
plying total charges by the hospital’s global cost-to-charge
ratio from the annual Medicare Cost Report for each
hospital (10,11). This methodology, comparing departmen-
tal with whole hospital cost-to-charge ratios, was validated
in 1,676 patients undergoing angioplasty at Emory Univer-
sity in 1995. If CD is cost from departmental cost-to-charge
ratios and CH is cost the whole hospital cost-to-charge
ratio, then CH 5 0.83 3 CD 1 170. The R
2 was 0.97, and
the intercept of 170 was just 2% of the mean whole hospital
cost of $8,493. Assuming that CD is a better estimate of cost
than CH and that the relationship from Emory between CD
and CH holds at other hospitals, then the equation would
result in an underestimate of cost for low-cost hospitaliza-
tions and an overestimate for high-cost hospitalizations,
biasing against a form of therapy that limits costs mostly in
higher cost patients by preventing complications.
An estimate of physician costs was derived using a model
for physician costs based on a profile of services provided for
interventional procedures at Emory University (12). The
Emory Clinic’s centralized billing system was used to assess
all physician resource use for patients undergoing coronary
intervention during any episode of care. The physician cost
was derived by converting each CPT code for each service to
resource value units (RVUs) (12). The RVUs were then
summed and converted to cost using the Medicare conver-
sion factor (12).
The cost of tirofiban was estimated at $700, based on two
Table 1. Linear Regression Model to Predict In-Hospital Cost
Variable
Parameter
Estimate
95%
Confidence
Interval
T
Value
p
Value
Initial hospital length of stay 767 676–857 15.8 , 0.0001
Coronary surgery during initial hospitalization 14,461 12,339–16,583 13.6 , 0.0001
Additional coronary angioplasty 4,925 3535–6315 7.1 , 0.0001
Stent for bailout or inadequate result 2,995 1,538–4,451 4.1 , 0.0001
Myocardial infarction at presentation 1,146 588–1,745 4.0 , 0.0001
Congestive failure 2,508 1,192–3,824 3.8 , 0.0001
Myocardial infarction as a complication 1,605 263–2,947 2.4 0.017
R2 5 0.57.
Abbreviations and Acronyms:
EPIC 5 Evaluation of 7E3 for the Prevention of
Ischemic Complications
EPILOG 5 Evaluation of PTCA to Improve Long-
Term Outcome by C7ES GPIIb/IIIa
Receptor blockade
IMPACT 5 Integrilin to Minimize Platelet
Aggregation and Prevent Coronary
Thrombosis
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
RESTORE 5 Randomized Efficacy Study of Tirofiban
for Outcomes and Restenosis trial
RVUs 5 resource value units
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50-ml vials of tirofiban injection at a catalogue price of $350
each. Hospital and physician costs for U.S. patients for
whom costs were not measured were imputed using a linear
regression model with major clinical and outcome variables
as independent variables (Table 1). The most important
clinical determinants of cost were coronary surgery, additional
angioplasty, MI and intracoronary stent placement. A history
of congestive heart failure and a MI at presentation were also
determinants of cost. Length of stay was included in the model
to permit the best possible estimate of cost (R2 5 0.57).
Data analysis. Categorical data are presented as counts and
percentages. Continuous data are presented as mean 6
standard deviation, and as median and interquartile range
when the assumption of normality is violated. Categorical
data were compared by chi-square or Fisher exact test where
appropriate. Continuous data were compared by t test or by
Wilcoxon rank sum test where the assumption of normality
is violated. Data on events used for resource utilization in this
study will vary somewhat from end point data in the main trial
(7) because resource use will consider all events, rather than the
somewhat more narrowly defined clinical end points. Data
were analyzed with SAS (SAS Institute Inc., Cary, North
Carolina) and S-Plus (MathSoft, Seattle, Washington).
RESULTS
The patients in the RESTORE trial (Table 2) were typical
of patients undergoing angioplasty in the setting of acute
ischemic syndromes. There was no difference noted between
the two treatment arms for any baseline clinical variable and
no difference between the total group in the U.S. and the
patients for whom costs were available. Two- and 30-day
clinical outcome data for all U.S. patients are displayed in
Table 3. At two days, the composite event rate was 36%
lower for tirofiban compared with placebo (8% vs. 12%, p 5
0.002). This benefit reflected a reduction in nonfatal MI
and repeat angioplasty, as well as trends toward reductions
in coronary surgery and stent usage. The data indicated a
similar trend in clinical benefit at 30 days, with a 16%
reduction in events. When the clinical event data were
analyzed for patients included in the cost substudy, the
Table 3. Clinical Outcome Data for All U.S. Patients
Placebo
(n 5 963)
Tirofiban
(n 5 957) Risk Reduction p Value
First 2 days
Total end points 119 (12.4) 77 (8.0) 36% 0.002
Myocardial infarction 53 (5.5) 31 (3.2) 42% 0.015
Death 2 (0.2) 2 (0.2) — 1.00
Repeat angioplasty 38 (3.9) 13 (1.4) 64% 0.001
Coronary surgery 15 (1.6) 9 (0.9) 44% 0.22
Stent 52 (5.4) 41 (4.3) 20% 0.26
30 days
Total end points 165 (17.1) 138 (14.4) 16% 0.10
Myocardial infarction 70 (7.3) 52 (5.4) 26% 0.10
Death 6 (0.6) 9 (0.9) — 0.43
Repeat angioplasty 72 (7.5) 55 (5.7) 24% 0.13
Coronary surgery 23 (2.4) 22 (2.3) 4% 0.90
Stent 52 (5.4) 41 (4.3) 20% 0.26
Table 2. Baseline Clinical Characteristics for Economic Substudy
All U.S. Patients Patients in Cost Substudy
Placebo
(n 5 963)
Tirofiban
(n 5 957)
Placebo
(n 5 419)
Tirofiban
(n 5 401)
Mean age (years) 59.2 59.0 58.8 58.9
Male 72.7% 72.0% 72.8% 69.3%
Risk factors
Diabetes 19.9% 20.7% 18.9% 21.9%
Hypertension 57.3% 55.4% 57.5% 54.4%
History of smoking 66.8% 64.1% 62.5% 62.8%
Previous myocardial infarction 39.3% 36.5% 35.3% 35.4%
Previous procedure
Coronary angioplasty 20.5% 20.8% 17.7% 18.0%
Coronary surgery 8.3% 6.9% 6.9% 7.5%
Study inclusion acute myocardial
infarction
32.3% 32.1% 35.1% 34.9%
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results were similar (Table 4). There was a 46% reduction in
events with tirofiban compared with placebo (7.0% vs.
12.9%, p 5 0.005). At 30 days, there was a 28% reduction
in the composite event rate with tirofiban compared with
placebo (12.7% vs. 17.7%, p 5 0.049). Direct costs are
compared in Table 5. Initial hospital costs, both in those
patients for whom costs were measured (n 5 820) and in all
U.S. patients (with imputed costs where measured costs
were not available), were not shown to differ between the
two arms. In the patients for whom costs were measured,
the mean initial hospital cost was $10,289 with placebo
versus $10,551 with tirofiban (p 5 0.52). The linear
regression model was used to impute costs in all U.S.
patients for whom cost data were not collected in
RESTORE. There was no significant treatment difference
noted in either the initial hospital costs (with the cost of
tirofiban included) or the initial professional costs. Thus,
the total cost for the initial hospitalization was not shown to
differ between the two arms ($12,145 and $12,230 for
placebo and tirofiban, respectively). Similarly, at 30 days,
the hospital costs and the sum of hospital plus professional
costs at $12,402 in the placebo arm and $12,446 in the
tirofiban arm were not noted to differ.
The cumulative distribution of initial hospital cost for
patients in the cost study is displayed in Figure 1. The cost
curves are similar, although there is a suggestion of higher
costs in the tirofiban arm for lower cost patients (due to the
added cost of tirofiban) and lower cost in the tirofiban arm
for higher cost patients (due to fewer complications with
tirofiban). This is consistent with tirofiban decreasing cost
in higher-cost patients by preventing costly events. The
wide dispersion and tail of higher cost patients may be
noted. Similarly, the cumulative distribution of hospital cost
for all U.S. patients is displayed in Figure 2. While essential
overlap exists, it is important to note there is wide variability
in cost and some patients at higher cost. Cumulative mean
cost over time is displayed in Figure 3, in which the overlap
of the two arms may be noted once again.
DISCUSSION
The nonpeptide GPIIb/IIIa receptor blocker tirofiban has
been shown to decrease adverse clinical events after coronary
intervention (7) and in the setting of unstable angina
(13,14). The clinical results are similar to those noted with
the antibody fragment, abciximab (5). In the present study,
Table 4. Clinical Outcome Data for Cost Substudy Patients
Placebo
(n 5 419)
Tirofiban
(n 5 401) Risk Reduction p Value
First 2 days
Total end points 54 (12.9) 28 (7.0) 46% 0.005
Myocardial infarction 23 (5.5) 14 (3.5) 36% 0.17
Death 2 (0.5) 0 (0) 100% 0.17
Repeat angioplasty 19 (4.5) 7 (1.7) 62% 0.023
Coronary surgery 8 (1.9) 1 (0.2) 87% 0.023
Stent 20 (4.8) 10 (2.5) 48% 0.082
30 days
Total end points 74 (17.7) 51 (12.7) 28% 0.049
Myocardial infarction 31 (7.4) 20 (5.0) 32% 0.15
Death 3 (0.7) 3 (0.7) — 0.96
Repeat angioplasty 37 (6.8) 23 (5.7) 35% 0.089
Coronary surgery 12 (2.9) 7 (1.7) 41% 0.29
Stent 20 (4.8) 10 (2.5) 48% 0.082
Table 5. Mean Cost Data (6 SD)
Measure of Cost Placebo Tirofiban p Value
Cost study patients
Measured initial hospital cost $10,289 6 6,241 $10,551 6 5,388 0.52
30-day hospital costs $10,717 6 6,615 $10,914 6 5,909 0.65
All patients
Initial hospital costs: all patients $10,319 6 5,419 $10,394 6 5,038 0.75
Initial professional costs $1,830 6 559 $1,836 6 568 0.82
Initial hospital 1 professional costs $12,145 6 5,882 $12,230 6 5,527 0.75
30-day hospital costs $10,505 6 6,413 $10,545 6 5,284 0.87
30-day hospital 1 professional costs $12,402 6 6,147 $12,446 6 5,814 0.87
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we have shown that these favorable results can be achieved
at essentially no increased cost, due to the decreased
cardiovascular events (i.e., a decrease in additional angio-
plasty, stent placement and coronary surgery). These data
may be compared with cost data with abciximab noted in
the Evaluation of 7E3 for the Prevention of Ischemic
Complications (EPIC) study (15). In EPIC, exclusive of
drug cost, the initial cost was $13,577 in the active treat-
ment arm versus $13,434 with placebo, a cost increase of
$143 that was related to increased bleeding (14). This
compares with an initial hospital and professional cost of
$12,230 with tirofiban and $12,145 with placebo in the
present study, with the $700 cost of the tirofiban included in
the active treatment arm.
Review of GPIIb/IIIa trials. GPIIb/IIIa blockers have
established efficacy in decreasing events in the setting of
high-risk angioplasty (5–7) and unstable angina (13,14). How-
ever, risk stratification to identify the population for whom
these agents will prove economically attractive will require
additional study (16). While the recently completed Evaluation
of PTCA to Improve Long-Term Outcome by C7E3 GPIIb/
IIIa Receptor Blockade (EPILOG) (17) and Integrilin to
Minimize Platelet Aggregation and Prevent Coronary Throm-
bosis (IMPACT II) (6) trials suggested that these agents
might be useful in wider patient groups, more data are needed
to assess the cost-effectiveness of GPIIb/IIIa blockade in lower
risk subgroups. Thus, additional studies in low-risk patients
may be appropriate.
To date, studies have utilized a bolus or loading infusion
followed by a maintenance intravenous infusion. Oral or
transdermal GPIIb/IIIa blockers or other antiplatelet agents
may extend and improve the utility of intravenous GPIIb/
IIIa blockade in the current target populations of unstable
angina and high-risk angioplasty. In addition, oral platelet
blockade may extend the use of these agents into other
patient categories. Given the emerging focus on value in
healthcare (cost/outcome), establishing the cost and where
appropriate and feasible the cost-effectiveness of these
agents will be essential.
Figure 1. Cumulative costs in the two treatment arms in the cost
substudy patients.
Figure 2. Cumulative costs in the two treatment arms in all U.S.
patients.
Figure 3. Cumulative costs over time in the two treatment arms in
all U.S. patients.
1065JACC Vol. 34, No. 4, 1999 Weintraub et al.
October 1999:1061–6 RESTORE Trial Economics
Limitations of economic methods in clinical trials. Eco-
nomic studies within randomized trials have limitations and
require careful interpretation. The hospital costs in this
study were derived from the UB92 formulation of the
hospital bill. The charges on these bills were reduced to
costs using whole hospital cost-to-charge ratios. While
departmental cost-to-charge ratios may seem more appro-
priate, there are data that suggest that the whole hospital
cost-to-charge ratio is more accurate (18). More impor-
tantly, the accuracy of the costs in this study is dependent on
the hospital cost reports that are filed annually with the
Health Care Financing Agency. Although hospitals have a
strong incentive to be accurate in this reporting, it is beyond
the ability of this study (or essentially any cost study of this
type) to audit the accuracy of cost data.
Professional costs in this trial were based on a model
developed in a larger data set at Emory University. While it
is easy to criticize these costs as unrepresentative results from
one institution, it is probably more meaningful to at least try to
account for all professional activity by developing a profile of
the distribution of professional activity rather than simply
assigning a cost for professional activity to a hospitalization.
It must also be recognized that reimbursement, as well as
costs, are changing over time in complex ways. In economic
studies, costs are often inflated or deflated to a particular
year using the medical inflation rate. However, hospitals
have made a great effort to increase efficiency of delivery of
health care services, specifically, expensive types of care such
as angioplasty. Thus, costs may actually be decreasing while
the medical inflation rate is otherwise increasing.
Assessing complete costs has also been a tremendous
challenge in medical microeconomic studies. Establishing costs
after an initial hospitalization, which may include follow-up
hospitalizations at outlying hospitals, is often difficult. Assess-
ing all outpatient direct and indirect costs is difficult and is
rarely achieved. Although in cost studies it is generally best to
present data from a societal perspective, costs are necessarily
accumulated from provider, payer and patient perspectives.
Societal costs may be created from these data, recognizing that
the data may not always be true societal costs.
Conclusions. In this study, we have shown that the GPIIb/
IIIa blocker tirofiban can reduce complications in patients with
acute coronary syndromes after angioplasty at no increase in
cost, given the limitations of measurement reviewed above. It is
difficult for even an effective drug to decrease costs when it
decreases the rate of events in only a minority of patients;
consequently, cost probably will rise for many patients. How-
ever, it will decrease, perhaps dramatically, in patients for
whom complications are prevented. Overall, these data are
consistent with other agents in the class, and with tirofiban,
there was the added benefit that the end point risk reduction
was not offset by significant increased bleeding. Finally, the
economic analysis in RESTORE suggests the clinical benefit
can be achieved at no additional cost in high-risk patients
during the initial hospitalization and at 30 days.
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